glp 1 long term safety 🧠 Researchers are exploring whether GLP-1 medications used for #diabetes and weight loss could treat #Alzheimers and addiction, but public concerns persist about long-term safety. 🔗 Read the full article at beingpatient.com # GLP-1 receptor agonism: a transformative

Also published in the New England Journal of Medicine in 2022, the SURMOUNT-1 trial demonstrated that tirzepatide at the 15 mg dose produced an average weight loss of 22.5% of body weight over 72 weeks approaching results typically seen with bariatric surgery (Jastreboff et al., 2022, PMID: 35658024)

September 11, 2023

GLP-1 is a hormone produced in the small intestine that stimulates insulin sensitivity and inhibits glucagon secretion, thereby lowering blood sugar

Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study